- 专利标题： Compounds for the treatment of hepatitis C
-
申请号： US12904264申请日： 2010-10-14
-
公开(公告)号： US08586584B2公开(公告)日： 2013-11-19
- 发明人: Tao Wang , Annapurna Pendri , Zhongxing Zhang , Weixu Zhai , Guo Li , Samuel Gerritz , Paul Michael Scola , Li-Qiang Sun , Qian Zhao , Eric Mull
- 申请人： Tao Wang , Annapurna Pendri , Zhongxing Zhang , Weixu Zhai , Guo Li , Samuel Gerritz , Paul Michael Scola , Li-Qiang Sun , Qian Zhao , Eric Mull
- 申请人地址： US NJ Princeton
- 专利权人： Bristol-Myers Squibb Company
- 当前专利权人： Bristol-Myers Squibb Company
- 当前专利权人地址： US NJ Princeton
- 代理商 James Epperson
- 主分类号： A61K31/53
- IPC分类号： A61K31/53 ; C07D251/72 ; C07D487/00
摘要：
The disclosure provides compounds of formula I, including pharmaceutically acceptable salts, as well as compositions and methods of using the compounds. The compounds have activity against hepatitis C virus (HCV) and may be useful in treating those infected with HCV.
公开/授权文献
- US20110086858A1 Compounds for the Treatment of Hepatitis C 公开/授权日：2011-04-14
信息查询
